The prefrontal cortex as a target for the atypical antipsychotic RU-31 with 5-HT2A antagonistic activity in the treatment of cognitive symptoms

Authors

DOI:

https://doi.org/10.18413/rrpharmacology.11.537

Abstract

Introduction: Cognitive deficits in schizophrenia are poorly managed by current antipsychotics, making the 5-HT2A receptor a promising therapeutic target, given its influence on dopaminergic signaling in the prefrontal cortex (PFC) and its involvement in cognitive processes. RU-31 (1-(2-diethylaminoethyl)-2-(4-methoxyphenyl)-imidazo[1,2-a]benzimidazole), a selective 5-HT2A antagonist, may offer cognitive benefits without the side effects associated with traditional dopamine-targeted therapies.

Materials and Methods: We evaluated RU-31 in Sprague-Dawley rats using molecular modeling, in vivo behavioral testing, and ex vivo electrophysiology. Molecular docking and dynamics simulations assessed the binding properties of RU-31 to the 5-HT2A receptor. The prepulse inhibition (PPI) paradigm (n=40) was used to test sensorimotor gating following a single RU-31 microinjection into the PFC. Patch-clamp recordings (n=32) from PFC pyramidal neurons were used to investigate RU-31's effects on serotonergic signaling.

Results: Molecular modeling indicated a strong binding affinity of RU-31 to the 5-HT2A receptor (100 ns). RU-31 (30 μg) restored PPI levels by 34.94% (p<0.05) following ketamine-induced deficits, suggesting an improvement in sensorimotor gating. In patch-clamp recordings, RU-31 (10 μM) significantly reduced 5-HT-mediated outward currents in layer 6 pyramidal neurons by 59.11% to 20.54 pA (SEM=7.12; SD=20.14; p<0.0211), indicating potent 5-HT2A antagonism and potential enhancement of downstream signaling.

Conclusion: This study establishes RU-31 as a promising therapeutic agent for the cognitive symptoms of schizophrenia, demonstrating that it reverses deficits in sensorimotor gating and normalizes PFC neuronal activity through selective 5-HT2A antagonism.

Graphical Abstract

Keywords:

atypical antipsychotics, 5-HT2A receptors, benzimidazoles, molecular docking, molecular dynamics, patch clamp, prepulse inhibition, prefrontal cortex, schizophrenia, cognitive deficits

References

Bortolozzi A, Masana M, Díaz-Mataix L, Cortés R, Scorza MC, Gingrich JA, Toth M, Artigas F (2010) Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors. The International Journal of Neuropsychopharmacology 13(10): 1299–1314. https://doi.org/10.1017/S146114571000009X[PubMed] [PMC]

Bubser M, Koch M (1994) Prepulse inhibition of the acoustic startle response of rats is reduced by 6-hydroxydopamine lesions of the medial prefrontal cortex. Psychopharmacology 113(3-4): 487–492. https://doi.org/10.1007/BF02245228 [PubMed]

Celada P, Puig MV, Artigas F (2013) Serotonin modulation of cortical neurons and networks. Frontiers in Integrative Neuroscience 7: 25. https://doi.org/10.3389/fnint.2013.00025 [PubMed] [PMC]

De Deurwaerdère P, Chagraoui A, Di Giovanni G (2021) Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence. Progress in Brain Research 261: 161–264. https://doi.org/10.1016/bs.pbr.2021.02.001 [PubMed]

Frohlich J, Van Horn JD (2014) Reviewing the ketamine model for schizophrenia. Journal of Psychopharmacology (Oxford, England) 28(4): 287–302. https://doi.org/10.1177/0269881113512909

Gebreegziabhere Y, Habatmu K, Mihretu A, Cella M, Alem A (2022) Cognitive impairment in people with schizophrenia: an umbrella review. European Archives of Psychiatry and Clinical Neuroscience 272(7): 1139–1155. https://doi.org/10.1007/s00406-022-01416-6 [PubMed] [PMC]

Habtewold TD, Rodijk LH, Liemburg EJ, Sidorenkov G, Boezen HM, Bruggeman R, Alizadeh B Z (2020) A systematic review and narrative synthesis of data-driven studies in schizophrenia symptoms and cognitive deficits. Translational Psychiatry 10(1): 244. https://doi.org/10.1038/s41398-020-00919-x [PubMed] [PMC]

Hanson KL, Grant SE, Funk LH, Schumann CM, Bauman MD (2022) Impact of maternal immune activation on nonhuman primate prefrontal cortex development: insights for schizophrenia. Biological Psychiatry 92(6): 460–469. https://doi.org/10.1016/j.biopsych.2022.04.004 [PubMed] [PMC]

Howes OD, Bukala BR, Beck K (2024) Schizophrenia: from neurochemistry to circuits, symptoms and treatments. Nature Reviews. Neurology 20(1): 22–35. https://doi.org/10.1038/s41582-023-00904-0 [PubMed]

Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O’Laughlin IA, Meltzer HY (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 76(5): 1521–1531. https://doi.org/10.1046/j.1471-4159.2001.00154.x[PubMed]

Kalitin KY, Pridvorov GV, Spasov AA, Mukha OY (2022) Effect of clozapine and 5-HT2A-antagonist RU-31 on electroencephalography and motor activity of rats in a model of schizophrenia with neonatal destruction of the ventral hippocampus. Kuban Scientific Medical Bulletin 29(5): 108-122. https://doi.org/10.25207/1608-6228-2022-29-5-108-122

Lobo MC, Whitehurst TS, Kaar SJ, Howes OD (2022) New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neuroscience and Biobehavioral Reviews 132: 324–361. https://doi.org/10.1016/j.neubiorev.2021.11.032 [PubMed]

López-Gil X, Babot Z, Amargós-Bosch M, Suñol C, Artigas F, Adell A (2007) Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 32(10): 2087–2097. https://doi.org/10.1038/sj.npp.1301356 [PubMed]

McCutcheon RA, Keefe RS.E, McGuire PK (2023) Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Molecular Psychiatry 28(5): 1902–1918. https://doi.org/10.1038/s41380-023-01949-9 [PubMed] [PMC]

McLean SL, Harte MK, Neill JC, Young AM (2017) Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: A preliminary investigation. Journal of Psychopharmacology (Oxford, England) 31(6): 660–666. https://doi.org/10.1177/0269881117704988 [PubMed]

Menon, V, D'Esposito M (2022) The role of PFC networks in cognitive control and executive function. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 47(1): 90–103. https://doi.org/10.1038/s41386-021-01152-w[PubMed] [PMC]

Mocci G, Jiménez-Sánchez L, Adell A, Cortés R, Artigas F (2014). Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action. Neuropharmacology 79: 49–58. https://doi.org/10.1016/j.neuropharm.2013.10.021 [PubMed]

Nikolaus S, Chao OY, Henke J, Beu M, Fazari B, Almeida FR, Abdel-Hafiz L, Antke C, Hautzel H, Mamlins E, Müller HW, Huston JP, von Gall C, Giesel FL (2024) 5-HT1A and 5-HT2A receptor effects on recognition memory, motor/exploratory behaviors, emotionality and regional dopamine transporter binding in the rat. Behavioural Brain Research 469: 115051. https://doi.org/10.1016/j.bbr.2024.115051 [PubMed]

Pelevin A, Kurzina N, Zavialov V, Volnova A (2023) A custom solution for acoustic startle response setup with spike2-based data acquisition interface. Methods and Protocols 6(3): 57. https://doi.org/10.3390/mps6030057 [PubMed] [PMC]

Singh S, Khanna D, Kalra S (2020) Role of neurochemicals in schizophrenia. Current Psychopharmacology 9(2): 144-161. https://doi.org/10.2174/2211556009666200401150756

Swerdlow NR, Light GA (2016) Animal models of deficient sensorimotor gating in schizophrenia: are they still relevant?. Current Topics in Behavioral Neurosciences 28: 305–325. https://doi.org/10.1007/7854_2015_5012 [PubMed]

Tian MK, Schmidt EF, Lambe EK (2016) Serotonergic suppression of mouse prefrontal circuits implicated in task attention. eNeuro 3(5): ENEURO.0269-16.2016. https://doi.org/10.1523/ENEURO.0269-16.2016 [PubMed] [PMC]

Author Contribution

Konstantin Y. Kalitin, Volgograd State Medical University

PhD, Associate Professor of the Department of Pharmacology and Bioinformatics, Volgograd State Medical University, Volgograd, Russia; Senior Researcher, Laboratory of Metabotropic Drugs, Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia; Senior Researcher, Laboratory of Synaptic Biology (Priority 2030) of Southern Federal University, Rostov-on-Don, Russia; e-mail: kkonst8@yandex.ru; ORCID ID: https://orcid.org/0000-0002-0079-853X. Conceptualization, setting primary objectives, carrying out experimental procedures, analyzing and interpreting the data, writing the initial draft of the article, contributing to the overall structure and design, finalizing the article for submission, designing visual data representations, applying statistical, mathematical, and computational methods for data analysis.

Olga Y. Mukha, Volgograd State Medical University

Assistant of the Department of Pharmacology and Bioinformatics, Volgograd State Medical University, Volgograd, Russia; Junior Researcher, Laboratory of Metabotropic Drugs, Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia; e-mail: myha14@gmail.com; ORCID ID: https://orcid.org/0000-0002-0429-905X. Task management, experimental work, literature review, data collection, drafting the manuscript, contributing to the scientific layout, ensuring the integrity and consistency of the entire article, including its final version; application of statistical, mathematical, and computational methods for data analysis, preparation of the final manuscript, interaction with the editors and reviewers.

Viktor B. Voynov, Southern Federal University

PhD, Chief Researcher at the Laboratory of Synaptic Biology (Priority 2030) of Southern Federal University, Rostov-on-Don, Russia; e-mail: vvoynov@sfedu.ru; ORCID ID:https://orcid.org/0000-0002-0242-6270. Literature review, drafting the manuscript, contributing to the scientific layout, ensuring the integrity and consistency of the entire article, including its final version; and preparation of the final manuscript.

Alexander A. Spasov, Volgograd State Medical University

PhD, Professor, Full member of the of the Russian Academy of Sciences; Head of the Department of Pharmacology and Bioinformatics, Volgograd State Medical University, Volgograd, Russia; Head of the Department of Pharmacology and Bioinformatics, Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia; e-mail: aaspasov@volgmed.ru; ORCID ID: https://orcid.org/0000-0002-7185-4826. Concept statement, supervision and mentorship, workflow control, critical revision with valuable intellectual investment, contributing to the overall structure and design, ensuring the integrity and consistency of the entire article.

Downloads

Published

30-09-2025

How to Cite

Kalitin KY, Mukha OY, Voynov VB, Spasov AA (2025) The prefrontal cortex as a target for the atypical antipsychotic RU-31 with 5-HT2A antagonistic activity in the treatment of cognitive symptoms. Research Results in Pharmacology 11(3): 98–108. https://doi.org/10.18413/rrpharmacology.11.537

Issue

Vol. 11 No. 3 (2025)

Section

Experimental Pharmacology

License

Copyright (c) 2025 Kalitin KY, Mukha OY, Voynov VB, Spasov AA

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)

<< < 1 2